Alez Afaei

This week, the FDA granted approval for Merck & Co., Inc. (NYSE: MRK)’s Keyruda for chemotherapy combination treatment of frontline lung cancer. While the approval was far from a surprise, it may be enough to move the needle for both Merck and rival Bristol-Myers Squibb Co (NYSE: BMY)....